| Name | Title | Contact Details |
|---|
SynGen advances regenerative medicine and other emerging applications for high-value cells by providing researchers, clinicians and manufacturers with innovative, robust systems that improve the recovery, purity and viability of stem and other clinically important cells from umbilical cord blood, peripheral blood, bone marrow, and cell culture.
Our mission at Aveda is to care for the world we live in, from the products we make to the ways in which we give back to society.
Prognosis Health Information Systems (PROGNOSIS) is the progeny of an eight year old hospital business software vendor and a thirty-five year old medical records service and software provider which have provided products and services to hospitals across America.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.
OPCO Laboratory Inc is a Fitchburg, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.